CRS/ICANS incidence, associations, and clinical outcomes. (A) Table of CRS and ICANS incidence by maximum grade and glofitamab dose. (B) Bar graph of CRS events by glofitamab dose. (C) Forest plot summarizing univariable Cox regressions for CRS (any grade) by baseline pretreatment characteristics. (D-F) Kaplan-Meier curves for PFS (D), overall survival (E), and PFS by CRS incidence (F). ALC, absolute lymphocyte count; C1D1, cycle 1 day 1; ECOG PS, Eastern Cooperative Oncology Group Performance Status; OR, odds ratio; ULN, upper limit of normal.